Following President-elect Donald Trump’s victory, executives from the top five pharmaceutical companies reportedly held an emergency meeting to discuss potential regulatory shake-ups. Concerns have intensified with Robert F. Kennedy Jr., an outspoken critic of federal health agencies, set to play a significant role in restructuring public health regulations under the new administration.
Jamel Holley, a New Jersey assemblyman and advisor to Kennedy, stated, “The top CEOs are in a state of panic,” adding that the teleconference addressed a new “threat environment” as the pharmaceutical sector braces for major policy shifts.